Metformin in Pregnancy and Lactation: What Every Woman Needs to Know

How Metformin Works: The Mechanism Behind the Pill

Metformin lowers blood glucose through three main actions, none of which involve stimulating insulin secretion. That distinction matters for women, especially during pregnancy, because it means metformin alone does not cause hypoglycemia.

Action 1: Suppressing Hepatic Glucose Output

The liver is the dominant target. Metformin inhibits mitochondrial complex I in hepatocytes, reducing the energy available to drive gluconeogenesis and glycogenolysis. The net result is a 25-36% reduction in fasting hepatic glucose production. In a woman with insulin resistance, whether from type 2 diabetes, PCOS, or the physiological insulin resistance of late pregnancy, this effect is particularly meaningful because the liver is often pumping out glucose even in a fasted state.

Action 2: Improving Peripheral Insulin Sensitivity

Metformin activates AMP-activated protein kinase (AMPK) in skeletal muscle, which increases GLUT4 transporter translocation to the cell surface. Glucose uptake improves without additional insulin secretion. AMPK activation also suppresses lipogenesis and reduces circulating free fatty acids, a mechanism relevant to women with PCOS who carry excess visceral adipose tissue.

Action 3: Slowing Intestinal Glucose Absorption

Metformin increases the gut's uptake of glucose into enterocytes and reduces net absorption into portal circulation. This action explains a portion of its GI side effects (nausea, diarrhea) and also contributes to modest postprandial glucose lowering.

These three pathways work together to lower fasting and postprandial glucose without driving hypoglycemia. That safety profile is one reason clinicians have been willing to use metformin during pregnancy, a situation where hypoglycemic episodes carry real risks for both mother and fetus.

Metformin Across Women's Life Stages

Metformin is not a one-size-fits-all drug. How it performs and what risks it carries shift depending on where you are in your reproductive life.

Reproductive Years (Pre-Pregnancy)

For women of reproductive age with type 2 diabetes or prediabetes, metformin is typically the first oral agent prescribed. The UKPDS 34 trial (Lancet, 1998) established its cardiovascular and glycemic benefits: overweight patients on metformin saw a 32% reduction in any diabetes-related endpoint compared with conventional diet therapy, with no increase in hypoglycemia. Because metformin does not cause weight gain and may support modest weight loss, it fits well for women managing the metabolic component of PCOS.

Menstrual cycle effects deserve specific attention. In women with PCOS and irregular cycles, metformin reduces hyperinsulinemia and lowers androgen levels, which can restore ovulation in 40-50% of anovulatory women within 6 months. This is a pharmacological effect that surprises some patients: your birth control plan matters even before you are actively trying to conceive, because metformin can unexpectedly restore fertility.

Trying to Conceive

Women with PCOS who are seeking pregnancy represent a large portion of metformin users in the fertility setting. ACOG Practice Bulletin No. 194 notes that metformin improves ovulation rates but that letrozole is now preferred as the first-line ovulation induction agent for most women with PCOS, given superior live birth rates shown in the PPCOS II trial. Metformin is still used, particularly when insulin resistance is significant, when letrozole has not succeeded alone, or in women who develop ovarian hyperstimulation syndrome risk.

If you are trying to conceive, discuss with your provider whether to continue metformin once a positive pregnancy test is confirmed. That decision is covered in detail in the section below.

Perimenopause and Post-Menopause

Insulin resistance worsens in perimenopause, partly because declining estradiol reduces pancreatic beta-cell sensitivity and increases visceral fat redistribution. Women who were managing prediabetes or PCOS-related metabolic dysfunction with metformin during their reproductive years often need continued or intensified therapy through menopause. There is a separate evidence gap worth naming here: most long-term metformin trials enrolled predominantly male cohorts. Women-specific data on metformin's effect on bone density (a relevant concern in post-menopause) and cardiovascular outcomes after menopause remains limited and largely extrapolated from mixed-sex studies.

Metformin in Pregnancy: What the Evidence Actually Shows

This is the section most women searching this topic need. The evidence is substantial but nuanced, and it does not all point in the same direction.

Placental Transfer and Fetal Exposure

Metformin crosses the placenta via organic cation transporters (OCT1, OCT3). Fetal plasma concentrations can reach approximately 50% of maternal concentrations at term. This is not a trace exposure. The fetus is pharmacologically exposed, which is why the question of fetal safety is taken seriously.

Does fetal exposure cause harm? The consistent finding across observational studies and randomized controlled trials is that metformin does not increase the rate of major congenital malformations above background population rates. A 2019 meta-analysis in Diabetes Care covering 7 RCTs and over 2,400 pregnancies found no significant difference in congenital anomaly rates between metformin and insulin-treated gestational diabetes (GDM). That is reassuring, but it does not fully resolve concerns about long-term offspring outcomes.

The MiG Trial: The Key RCT for GDM

The Metformin in Gestational Diabetes (MiG) trial, published in NEJM in 2008, randomized 751 women with GDM to metformin or insulin. Metformin was non-inferior to insulin for the composite neonatal outcome (neonatal hypoglycemia, respiratory distress, need for phototherapy, preterm birth, low 5-minute Apgar score, or neonatal intensive care admission). Women in the metformin group had lower rates of severe hypoglycemia and found the treatment more acceptable. However, 46.3% of the metformin group required supplemental insulin to achieve glycemic targets, which is a number worth discussing with your provider when setting expectations.

Offspring Follow-Up Data: A Reason for Ongoing Caution

Here is where the evidence becomes less comfortable. The MiG TOFU (Trial of Offspring Follow-Up) study followed the MiG children at age 2 and again at age 7-9. At age 7-9, children born to metformin-treated mothers had larger body size and increased fat mass compared with insulin-exposed children, though absolute differences were modest. A Norwegian cohort published in 2020 found similar signals of increased childhood BMI in offspring exposed to metformin in utero.

These findings do not establish causation. Confounding by maternal metabolic status is difficult to exclude. Still, they are enough that ACOG acknowledges both metformin and glyburide as alternatives to insulin in GDM while noting that long-term offspring data remain limited. This is an honest evidence gap, not a reason to panic if you are already on metformin during pregnancy.

First Trimester and Organogenesis: PCOS Pregnancies

Women with PCOS who conceive on metformin face a specific decision: stop at the positive test, or continue through the first trimester? The concern about stopping early is that PCOS pregnancies carry a higher miscarriage rate, and metformin may reduce that risk.

A Cochrane systematic review (2017) found that metformin reduced miscarriage rates in women with PCOS compared with placebo (relative risk 0.46, 95% CI 0.24 to 0.87), though the included trials were small and at moderate risk of bias. The ASRM Practice Committee notes insufficient evidence to recommend universal continuation of metformin through the first trimester in PCOS, but states that continuation is not contraindicated if the clinical picture supports it. This is a decision to make with your reproductive endocrinologist or MFM, not something to decide based on a Google search.

A practical decision framework for PCOS + pregnancy:

| Situation | Common approach | Evidence level | |---|---|---| | PCOS with prior miscarriage, ongoing insulin resistance | Continue metformin through first trimester with monitoring | Low-moderate RCT evidence | | PCOS, well-controlled glucose, no prior loss | Stop at positive pregnancy test or at 10-12 weeks | Expert consensus | | GDM diagnosed at 24-28 weeks, diet alone insufficient | Start metformin OR insulin; discuss supplemental insulin likelihood | High (MiG trial) | | Type 2 diabetes, pre-pregnancy | Transition to insulin before conception or at confirmed pregnancy; metformin may continue as adjunct | ACOG, ADA guidelines |

Pregnancy and Lactation Safety: The Required Summary

Pregnancy

Metformin was classified as FDA Pregnancy Category B under the old labeling system, meaning animal data showed no fetal risk and available human data did not demonstrate risk. Under the current FDA Pregnancy and Lactation Labeling Rule (PLLR), labels now include a narrative summary of available data rather than a letter grade. The current prescribing information for metformin states that published data from randomized trials and observational studies have not identified drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin is used during pregnancy.

That is not the same as proven safe. It means the data we have, across studies with significant sample sizes, do not show a signal for structural teratogenicity. Long-term offspring metabolic effects remain an open question.

Contraception requirement: Metformin is NOT a teratogen requiring mandatory contraception before use. Women of reproductive age on metformin do not need to use contraception specifically because of metformin. However, because metformin can restore ovulation in women with PCOS who were previously anovulatory, unexpected pregnancy is a real possibility. If you are not trying to conceive, discuss contraception with your provider once metformin is started.

Lactation

Metformin is present in breast milk at low concentrations. The most frequently cited pharmacokinetic study found infant daily doses of approximately 0.11-0.21 mg/kg/day through breast milk, representing roughly 0.28% of the weight-adjusted maternal dose. This is far below the 10% threshold that LactMed and most pharmacology authorities use to flag a drug as potentially concerning during breastfeeding.

No adverse effects in nursing infants from maternal metformin use have been documented in the published literature. LactMed (NIH) classifies metformin as acceptable during breastfeeding. The Academy of Breastfeeding Medicine and ACOG similarly support continued use during lactation.

Practical considerations for breastfeeding women: take metformin with food to minimize GI side effects, which are the most common reason women discontinue the drug. GI symptoms do not indicate that the drug is unsafe for your baby. If your infant shows any unusual symptoms (poor feeding, unusual lethargy, loose stools beyond normal newborn range), contact your pediatrician, though a causal link to metformin would be biologically implausible given the dose levels involved.

Who Metformin Is and Is Not Right For, by Life Stage

Women This Drug Typically Fits Well

• Type 2 diabetes, reproductive years: First-line oral agent. Low hypoglycemia risk, weight-neutral to modest weight loss, affordable.
• PCOS with insulin resistance: Strong mechanistic rationale; may restore ovulation and improve androgen levels. Useful alongside or before ovulation induction agents.
• Prediabetes (especially post-GDM): Women who had GDM carry a roughly 50% lifetime risk of developing type 2 diabetes. The Diabetes Prevention Program trial showed metformin reduced diabetes incidence by 31% in the high-risk group, with stronger effects in younger women and those with a prior GDM history.
• GDM, second or third trimester: A reasonable alternative to insulin for women who cannot or prefer not to inject, with the understanding that supplemental insulin may still be needed.
• Perimenopause with worsening insulin resistance: Continued use is appropriate with dose review as renal function may change with age.

Women Who Should Not Use Metformin or Need Extra Caution

• eGFR <30 mL/min/1.73m²: Contraindicated due to lactic acidosis risk. Women with chronic kidney disease from diabetic nephropathy or other causes need close monitoring; ACOG recommends discontinuing metformin if eGFR falls below 30.
• Planned radiographic contrast procedures: Hold metformin 48 hours before and after iodinated contrast due to transient renal impairment risk.
• Women with active hepatic disease: Lactic acidosis risk increases with impaired lactate clearance.
• Women using alcohol heavily: Alcohol potentiates lactic acidosis risk.
• Type 1 diabetes: Metformin is not indicated as monotherapy; insulin is the foundation of type 1 management, and metformin's use as adjunct in type 1 is off-label and not covered by most guidelines.

PCOS-Specific Considerations: Metformin Beyond Glucose

PCOS affects roughly 8-13% of women of reproductive age and is the most common endocrine disorder in this group. Many women with PCOS are prescribed metformin for reasons that extend well beyond blood glucose.

Androgen Reduction

By lowering insulin, metformin reduces ovarian androgen synthesis. Studies show modest reductions in free testosterone and DHEA-S, translating to some improvement in hirsutism and acne, though the effect size is smaller than what combined oral contraceptives or spironolactone provide. A 2018 Cochrane review found that metformin alone was less effective than oral contraceptives for managing hirsutism in PCOS, though the combination of both performed better than either alone.

Cycle Regulation in Perimenopause with PCOS

Women with PCOS who enter perimenopause face a complicated overlap of irregular cycles from two different causes: declining ovarian reserve and the background of anovulation from PCOS. Metformin does not treat perimenopause-related cycle irregularity. If you are perimenopausal and your cycles are changing, that conversation needs to include FSH, estradiol, and AMH levels, not just metabolic management.

Weight and GLP-1 Overlap

GLP-1 receptor agonists (semaglutide, tirzepatide) have largely surpassed metformin for weight loss in women with obesity and type 2 diabetes or PCOS. Metformin produces a median weight loss of 2-3 kg over 12 months in most trials, which is modest. For women whose primary goal is significant weight reduction, GLP-1 agents or dual GIP/GLP-1 agonists are now preferred. However, metformin remains a useful, inexpensive adjunct and is sometimes continued alongside a GLP-1 agent, particularly in women with type 2 diabetes where glycemic targets require more than one mechanism.

Dosing, Formulations, and Practical Guidance for Women

Standard metformin dosing starts at 500 mg once daily with the evening meal to minimize GI side effects, titrating by 500 mg per week to a typical target of 1,500-2,000 mg per day in divided doses. Extended-release formulations (metformin ER) produce lower peak plasma concentrations and are better tolerated GI-wise, though a 2023 FDA communication noted that some ER formulations had bioequivalence concerns and that patients should confirm their specific product with their pharmacist.

In pregnancy, dosing typically mirrors GDM trial protocols: the MiG trial started at 500 mg once or twice daily and titrated to a maximum of 2,500 mg per day. Do not self-adjust your dose during pregnancy without guidance from your OB or MFM.

B12 depletion is real and especially relevant to pregnant and postpartum women. Metformin reduces ileal B12 absorption through calcium-dependent mechanisms. Long-term use reduces B12 levels in approximately 10-30% of users. Because B12 deficiency causes neural tube defects and peripheral neuropathy, any woman on metformin who is pregnant, trying to conceive, or postpartum should have B12 levels checked annually and supplement if levels are trending low. Your prenatal vitamin may not contain enough B12 to compensate if absorption is significantly impaired.

A Note on the Evidence Gap for Women

Women have been underrepresented in metformin trials throughout the drug's history. The UKPDS 34 trial, the foundational cardiovascular outcomes study, enrolled a predominantly male cohort with only about 30% female participants. Sex-stratified analyses of metformin's effect on cardiovascular outcomes, cancer risk, and longevity pathways (metformin is being studied in the TAME trial for aging) have been limited. What we know about metformin's PK in women: women typically have lower renal tubular secretion of metformin than men of the same age and body size, which may result in modestly higher plasma concentrations at equivalent doses. This has not been incorporated into routine dosing guidelines, and the clinical significance in most women with normal renal function is low, but it is worth knowing that the standard dose recommendations were not derived from sex-stratified data.